Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Infection
Published in: Infection 2/2018

01-04-2018 | Brief Report

Antifungal activity of Myrtus communis against Malassezia sp. isolated from the skin of patients with pityriasis versicolor

Authors: Aleksandra Barac, Matthew Donadu, Donatella Usai, Vesna Tomic Spiric, Vittorio Mazzarello, Stefania Zanetti, Ema Aleksic, Goran Stevanovic, Natasa Nikolic, Salvatore Rubino

Published in: Infection | Issue 2/2018

Login to get access

Abstract

The increasing incidence of fungal infections and antifungal resistance has prompted the search for novel antifungal drugs and alternative agents. We explored the antifungal activity of Myrtus communis essential oil (EO) against Malassezia sp. isolated from the skin of patients with pityriasis versicolor. These broad-spectrum antimicrobial activities of M. communis EO and its potent inhibiting activity on Malassezia growth deserve further research with aim to considerate this EO as candidate for topical use in treatment of skin diseases.
Literature
1.
Gaitanis G, Velegraki A, Mayser P, Bassukas ID. Skin diseases associated with Malassezia yeasts: facts and controversies. Clin Dermatol. 2013;31:455–63.CrossRefPubMed
2.
Velegraki A, Cafarchia C, Gaitanis G, Iatta R, Boekhout T. Malassezia infections in humans and animals: pathophysiology, detection, and treatment. PLoS Pathog. 2015;11:e1004523.CrossRefPubMedPubMedCentral
3.
Sharma A, Rabha D, Ahmed G. In vitro antifungal susceptibility of Malassezia isolates from pityriasis versicolor lesions. Indian J Dermatol Venereol Leprol. 2017;83:249–51.CrossRefPubMed
4.
Pekmezovic M, Aleksic I, Barac A, Arsic-Arsenijevic V, Vasiljevic B, Nikodinovic-Runic J, Senerovic L. Prevention of polymicrobial biofilms composed of Pseudomonas aeruginosa and pathogenic fungi by essential oils from selected Citrus species. Pathog Dis. 2016;. https://​doi.​org/​10.​1093/​femspd/​ftw102.PubMed
5.
Ghasemi Pirbalouti A, Izadi A, Malek Poor F, Hamedi B. Chemical composition, antioxidant and antibacterial activities of essential oils from Ferulago angulata. Pharm Biol. 2016;54:2515–20.CrossRefPubMed
6.
Kordali S, Usanmaz A, Cakir A, Komaki A, Ercisli S. Antifungal and herbicidal effects of fruit essential oils of four Myrtus communis genotypes. Chem Biodivers. 2016;13:77–84.CrossRefPubMed
7.
Cannas S, Molicotti P, Ruggeri M, Cubeddu M, Sanguinetti M, Marongiu B, Zanetti S. Antimycotic activity of Myrtus communis L. towards Candida spp. from isolates. J Infect Dev Ctries. 2013;7:295–8.PubMed
8.
Deriu A, Branca G, Molicotti P, Pintore G, Chessa M, Tirillini B, Paglietti B, Mura A, Sechi LA, Fadda G, Zanetti S. In vitro activity of essential oil of Myrtus communis L. against Helicobacter pylori. Int J Antimicrob Agents. 2007;30:562–3.CrossRefPubMed
9.
Rodriquez-Tudela IL, Donnelly JP, Arendrup MC, Arikan S, Barchiesi F, Bille J, et al. EUCAST technical note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds. Clin Microbiol Infect. 2008;14:982–4.CrossRef
10.
Aleksic V, Knezevic P. Antimicrobial and antioxidative activity of extracts and essential oils of Myrtus communis L. Microbiol Res. 2014;169:240–54.CrossRefPubMed
Metadata
Title
Antifungal activity of Myrtus communis against Malassezia sp. isolated from the skin of patients with pityriasis versicolor
Authors
Aleksandra Barac
Matthew Donadu
Donatella Usai
Vesna Tomic Spiric
Vittorio Mazzarello
Stefania Zanetti
Ema Aleksic
Goran Stevanovic
Natasa Nikolic
Salvatore Rubino
Publication date
01-04-2018
Publisher
Springer Berlin Heidelberg
Published in
Infection / Issue 2/2018
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-017-1102-4

Other articles of this Issue 2/2018

Infection 2/2018 Go to the issue

Original Paper

Influence of antiviral therapy on the liver stiffness in chronic HBV hepatitis

Correspondence

Reply to comments: duration of antimicrobial therapy for Gram-negative bacteremia secondary to urinary source of infection

Case Report

First report of neonatal early-onset sepsis caused by multi-drug-resistant Raoultella ornithinolytica

Original Paper

The first report of Japanese antimicrobial use measured by national database based on health insurance claims data (2011–2013): comparison with sales data, and trend analysis stratified by antimicrobial category and age group

Correspondence

Is bacteremia the decisive factor for the duration of antimicrobial therapy in bacteremic urinary tract infections?

Original Paper

Alveolar echinococcosis in Germany, 1992–2016. An update based on the newly established national AE database
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits